Today: 30 April 2026
Browse Category

NASDAQ:ROIV 11 December 2025 - 8 February 2026

Roivant Sciences stock rockets after brepocitinib Phase 2 win — what ROIV investors watch next

Roivant Sciences stock rockets after brepocitinib Phase 2 win — what ROIV investors watch next

Roivant Sciences shares surged 22% to $25.82 Friday after the company reported positive Phase 2 data for brepocitinib in cutaneous sarcoidosis and filed for U.S. approval in dermatomyositis. Trading volume exceeded 24 million shares. Roivant posted a quarterly loss of $313.7 million on $2 million in revenue, with $4.5 billion in cash and equivalents.
8 February 2026
·
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
7 February 2026
··
Roivant Sciences (ROIV) Stock Surges After 2025 Investor Day: Pipeline Milestones, Cash Runway and Analyst Forecasts

Roivant Sciences (ROIV) Stock Surges After 2025 Investor Day: Pipeline Milestones, Cash Runway and Analyst Forecasts

Roivant Sciences shares climbed near $21.50 on December 11, approaching 52-week highs after the company’s Investor Day outlined plans for at least three product launches and four regulatory filings by 2028. The stock has gained about 85% over six months, pushing market value to roughly $15 billion. Management advanced timelines for key drug programs, including brepocitinib and IMVT-1402.
11 December 2025

Stock Market Today

  • SPY Rises 0.4% Driven by QCOM's 16.4% Surge and Strong Tech Gains
    April 30, 2026, 12:40 PM EDT. SPY, the S&P 500 ETF, climbed 0.4% supported by a 16.4% jump in Qualcomm (QCOM) shares today. Leading tech contributors included Alphabet's GOOGL and GOOG, up 7.1% and 6.9% respectively, alongside notable gains in Eli Lilly (LLY +9.4%) and Caterpillar (CAT +10.2%). Despite robust stock performance, QCOM insiders sold 40 times over six months without purchases, signaling potential caution. Analysts remain bullish with buy ratings from B of A Securities and Rosenblatt. The median price target for QCOM stands at $150, with top forecasts reaching as high as $190. Market participants eye Quiver Quantitative's dashboards for live SPY and QCOM data.

Latest article

Hertz Stock Surges on Uber Robotaxi Deal as Oro Mobility Steps Out of the Shadows

Hertz Stock Surges on Uber Robotaxi Deal as Oro Mobility Steps Out of the Shadows

30 April 2026
Hertz shares surged over 20% Thursday after it launched Oro Mobility, an affiliate set to manage Uber’s robotaxi and human-driven fleets in key U.S. markets. Oro will support Uber’s autonomous program with Lucid vehicles using Nuro self-driving tech, starting in the San Francisco Bay Area later this year. Hertz traded at $6.80, up $1.20; Uber fell 38 cents to $74.09. Hertz reports first-quarter results May 7.
Xerox Holdings Stock Soars After Q1 Revenue Beat, but the Lexmark Bill Is Still Showing

Xerox Holdings Stock Soars After Q1 Revenue Beat, but the Lexmark Bill Is Still Showing

30 April 2026
Xerox shares surged 43% Thursday after first-quarter revenue hit $1.85 billion, topping forecasts, driven by the Lexmark acquisition. The company posted a net loss of $105 million and an adjusted loss of 43 cents per share, wider than expected. Print segment revenue jumped 31%, while IT Solutions fell 5%. Xerox reaffirmed its 2026 outlook but reported higher interest expenses tied to acquisition debt.
Go toTop